Skip to main content
Erschienen in: European Radiology 8/2020

19.03.2020 | Interventional

Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know

verfasst von: Marco Calandri, Giulia Siravegna, Steven M. Yevich, Giuseppe Stranieri, Carlo Gazzera, Scott Kopetz, Paolo Fonio, Sanjay Gupta, Alberto Bardelli, Andrea Veltri, Bruno C. Odisio

Erschienen in: European Radiology | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

The acquisition of adequate tumor sample is required to verify primary tumor type and specific biomarkers and to assess response to therapy. Historically, invasive surgical procedures were the standard methods to acquire tumor samples until advancements in imaging and minimally invasive equipment facilitated the paradigm shift image-guided biopsy. Image-guided biopsy has improved sampling yield and minimized risk to the patient; however, there are still limitations, such as its invasive nature and its consequent limitations to longitudinal tumor monitoring. The next paradigm shift in sampling technique will need to address these issues to provide a more reliable and less invasive technique. Recently, liquid biopsy (LB) has emerged as a non-invasive alternative to tissue sampling. This technique relies on direct sampling of blood or other bodily fluids in contact with the tumor in order to collect circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and circulating RNAs—in particular microRNA (miRNAs). Clinical applications of LB involve different steps of cancer patient management including screening, detection of disease recurrence, and evaluation of acquired resistance. With any paradigm shift, old techniques are often relegated to a secondary option. Although image-guided biopsies may appear as a passive spectator on the rapid advancement of LB, the two techniques may well be codependent. Interventional radiology may be integral to directly sample the liquid surrounding or draining from the tumor. In addition, LB may help to correctly select the patients for image-guided loco-regional treatments, to determine its treatment endpoint, and to early detect recurrence.

Key Points

• Liquid biopsy is a novel technology with potential high impact in the management of patients undergoing image-guided procedures.
• Interventional radiology procedures may increase liquid biopsy sensitivity through direct fluid sampling.
• Liquid biopsy techniques may provide a venue for improving patients’ selection and enhance outcomes of interventional loco-regional therapies performed by interventional radiologists.
Literatur
1.
Zurück zum Zitat Prud’homme C, Deschamps F, Allorant A et al (2018) Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): what are the real risks? Eur J Cancer 103:108–119PubMed Prud’homme C, Deschamps F, Allorant A et al (2018) Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): what are the real risks? Eur J Cancer 103:108–119PubMed
3.
Zurück zum Zitat Chen P-L, Roh W, Reuben A et al (2016) Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov 6:827–837PubMedPubMedCentral Chen P-L, Roh W, Reuben A et al (2016) Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov 6:827–837PubMedPubMedCentral
4.
Zurück zum Zitat Overman MJ, Modak J, Kopetz S et al (2013) Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol 31:17–22PubMed Overman MJ, Modak J, Kopetz S et al (2013) Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol 31:17–22PubMed
5.
Zurück zum Zitat Siravegna G, Mussolin B, Buscarino M et al (2015) Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 21:795–801PubMedPubMedCentral Siravegna G, Mussolin B, Buscarino M et al (2015) Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 21:795–801PubMedPubMedCentral
6.
Zurück zum Zitat Siravegna G, Marsoni S, Siena S, Bardelli A (2017) Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol 14:531–548PubMed Siravegna G, Marsoni S, Siena S, Bardelli A (2017) Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol 14:531–548PubMed
7.
Zurück zum Zitat Ashworth TR (1869) A case of cancer in which cells similar to those in the tumors were seen in the blood after death. Med J Aust 14:146–147 Ashworth TR (1869) A case of cancer in which cells similar to those in the tumors were seen in the blood after death. Med J Aust 14:146–147
8.
Zurück zum Zitat Krebs MG, Hou J-M, Ward TH, Blackhall FH, Dive C (2010) Circulating tumour cells: their utility in cancer management and predicting outcomes. Ther Adv Med Oncol 2:351–365PubMedPubMedCentral Krebs MG, Hou J-M, Ward TH, Blackhall FH, Dive C (2010) Circulating tumour cells: their utility in cancer management and predicting outcomes. Ther Adv Med Oncol 2:351–365PubMedPubMedCentral
9.
Zurück zum Zitat Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C (2014) Molecular analysis of circulating tumour cells—biology and biomarkers. Nat Rev Clin Oncol 11:129–144PubMed Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C (2014) Molecular analysis of circulating tumour cells—biology and biomarkers. Nat Rev Clin Oncol 11:129–144PubMed
10.
Zurück zum Zitat Haber DA, Velculescu VE (2014) Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov 4:650–661PubMedPubMedCentral Haber DA, Velculescu VE (2014) Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov 4:650–661PubMedPubMedCentral
11.
Zurück zum Zitat Lin HK, Zheng S, Williams AJ et al (2010) Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res 16:5011–5018PubMedPubMedCentral Lin HK, Zheng S, Williams AJ et al (2010) Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res 16:5011–5018PubMedPubMedCentral
12.
Zurück zum Zitat Paterlini-Brechot P, Benali NL (2007) Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 253:180–204PubMed Paterlini-Brechot P, Benali NL (2007) Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 253:180–204PubMed
13.
Zurück zum Zitat Zhang L, Ridgway LD, Wetzel MD et al (2013) The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med 5:18048 Zhang L, Ridgway LD, Wetzel MD et al (2013) The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med 5:18048
14.
Zurück zum Zitat Ameri K, Luong R, Zhang H et al (2010) Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype. Br J Cancer 102:561–569PubMedPubMedCentral Ameri K, Luong R, Zhang H et al (2010) Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype. Br J Cancer 102:561–569PubMedPubMedCentral
15.
Zurück zum Zitat Cocucci E, Racchetti G, Meldolesi J (2009) Shedding microvesicles: artefacts no more. Trends Cell Biol 19:43–51PubMed Cocucci E, Racchetti G, Meldolesi J (2009) Shedding microvesicles: artefacts no more. Trends Cell Biol 19:43–51PubMed
16.
Zurück zum Zitat Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ (1999) Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 94:3791–3799PubMed Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ (1999) Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 94:3791–3799PubMed
17.
Zurück zum Zitat Pan B-T, Johnstone RM (1983) Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell 33:967–978PubMed Pan B-T, Johnstone RM (1983) Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell 33:967–978PubMed
18.
Zurück zum Zitat Simons M, Raposo G (2009) Exosomes – vesicular carriers for intercellular communication. Curr Opin Cell Biol 21:575–581PubMed Simons M, Raposo G (2009) Exosomes – vesicular carriers for intercellular communication. Curr Opin Cell Biol 21:575–581PubMed
19.
Zurück zum Zitat Mathivanan S, Ji H, Simpson RJ (2010) Exosomes: extracellular organelles important in intercellular communication. J Proteomics 73:1907–1920PubMed Mathivanan S, Ji H, Simpson RJ (2010) Exosomes: extracellular organelles important in intercellular communication. J Proteomics 73:1907–1920PubMed
20.
Zurück zum Zitat Liao J, Liu R, Yin L, Pu Y (2014) Expression profiling of exosomal miRNAs derived from human esophageal cancer cells by Solexa high-throughput sequencing. Int J Mol Sci 15:15530–15551PubMedPubMedCentral Liao J, Liu R, Yin L, Pu Y (2014) Expression profiling of exosomal miRNAs derived from human esophageal cancer cells by Solexa high-throughput sequencing. Int J Mol Sci 15:15530–15551PubMedPubMedCentral
21.
Zurück zum Zitat Wieckowski E, Whiteside TL (2006) Human tumor-derived vs dendritic cell-derived exosomes have distinct biologic roles and molecular profiles. Immunol Res 36:247–254PubMed Wieckowski E, Whiteside TL (2006) Human tumor-derived vs dendritic cell-derived exosomes have distinct biologic roles and molecular profiles. Immunol Res 36:247–254PubMed
22.
Zurück zum Zitat Lobb RJ, Becker M, Wen Wen S et al (2015) Optimized exosome isolation protocol for cell culture supernatant and human plasma. J Extracell Vesicles 4:27031 Lobb RJ, Becker M, Wen Wen S et al (2015) Optimized exosome isolation protocol for cell culture supernatant and human plasma. J Extracell Vesicles 4:27031
23.
Zurück zum Zitat Zhang J, Li S, Li L et al (2015) Exosome and exosomal MicroRNA: trafficking, sorting, and function. Genomics Proteomics Bioinformatics 13:17–24PubMedPubMedCentral Zhang J, Li S, Li L et al (2015) Exosome and exosomal MicroRNA: trafficking, sorting, and function. Genomics Proteomics Bioinformatics 13:17–24PubMedPubMedCentral
24.
Zurück zum Zitat Rani S, O’Brien K, Kelleher FC et al (2011) Isolation of exosomes for subsequent mRNA, MicroRNA, and protein profiling. In: O’Driscoll L (ed) Gene expression profiling. Humana Press, Totowa Rani S, O’Brien K, Kelleher FC et al (2011) Isolation of exosomes for subsequent mRNA, MicroRNA, and protein profiling. In: O’Driscoll L (ed) Gene expression profiling. Humana Press, Totowa
25.
Zurück zum Zitat Taylor DD, Gercel-Taylor C (2008) MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110:13–21PubMed Taylor DD, Gercel-Taylor C (2008) MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110:13–21PubMed
26.
Zurück zum Zitat Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13:423–433PubMedPubMedCentral Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13:423–433PubMedPubMedCentral
27.
Zurück zum Zitat Joosse SA, Pantel K (2015) Tumor-educated platelets as liquid biopsy in cancer patients. Cancer Cell 28:552–554PubMed Joosse SA, Pantel K (2015) Tumor-educated platelets as liquid biopsy in cancer patients. Cancer Cell 28:552–554PubMed
28.
Zurück zum Zitat Mitchell PS, Parkin RK, Kroh EM et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105:10513–10518PubMedPubMedCentral Mitchell PS, Parkin RK, Kroh EM et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105:10513–10518PubMedPubMedCentral
29.
Zurück zum Zitat Skog J, Würdinger T, van Rijn S et al (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10:1470–1476PubMedPubMedCentral Skog J, Würdinger T, van Rijn S et al (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10:1470–1476PubMedPubMedCentral
30.
Zurück zum Zitat Rabinowits G, Gerçel-Taylor C, Day JM, Taylor DD, Kloecker GH (2009) Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 10:42–46PubMed Rabinowits G, Gerçel-Taylor C, Day JM, Taylor DD, Kloecker GH (2009) Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 10:42–46PubMed
32.
Zurück zum Zitat Mandel P, Metais P (1948) Les acides nucléiques du plasma sanguin chez l’homme. C R Seances Soc Biol Fil 142:241–243PubMed Mandel P, Metais P (1948) Les acides nucléiques du plasma sanguin chez l’homme. C R Seances Soc Biol Fil 142:241–243PubMed
33.
Zurück zum Zitat Swarup V, Rajeswari MR (2007) Circulating (cell-free) nucleic acids - a promising, non-invasive tool for early detection of several human diseases. FEBS Lett 581:795–799PubMed Swarup V, Rajeswari MR (2007) Circulating (cell-free) nucleic acids - a promising, non-invasive tool for early detection of several human diseases. FEBS Lett 581:795–799PubMed
34.
Zurück zum Zitat Leon SA, Shapiro B, Sklaroff DM, Yaros MJ (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37:646–650PubMed Leon SA, Shapiro B, Sklaroff DM, Yaros MJ (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37:646–650PubMed
35.
Zurück zum Zitat Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M (1989) Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 46:318–322PubMed Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M (1989) Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 46:318–322PubMed
36.
Zurück zum Zitat Wang J-Y, Hsieh J-S, Chang M-Y et al (2004) Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg 28:721–726PubMed Wang J-Y, Hsieh J-S, Chang M-Y et al (2004) Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg 28:721–726PubMed
37.
Zurück zum Zitat Shaw JA, Smith BM, Walsh T et al (2000) Microsatellite alterations plasma DNA of primary breast cancer patients. Clin Cancer Res 6:1119–1124PubMed Shaw JA, Smith BM, Walsh T et al (2000) Microsatellite alterations plasma DNA of primary breast cancer patients. Clin Cancer Res 6:1119–1124PubMed
38.
Zurück zum Zitat Fujiwara K, Fujimoto N, Tabata M et al (2005) Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 11:1219–1225PubMed Fujiwara K, Fujimoto N, Tabata M et al (2005) Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 11:1219–1225PubMed
39.
Zurück zum Zitat Jahr S, Hentze H, Englisch S et al (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61:1659–1665PubMed Jahr S, Hentze H, Englisch S et al (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61:1659–1665PubMed
40.
Zurück zum Zitat Diehl F, Li M, Dressman D et al (2005) Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 102:16368–16373PubMedPubMedCentral Diehl F, Li M, Dressman D et al (2005) Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 102:16368–16373PubMedPubMedCentral
41.
Zurück zum Zitat Lo YMD, Zhang J, Leung TN, Lau TK, Chang AMZ, Hjelm NM (1999) Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 64:218–224PubMedPubMedCentral Lo YMD, Zhang J, Leung TN, Lau TK, Chang AMZ, Hjelm NM (1999) Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 64:218–224PubMedPubMedCentral
42.
Zurück zum Zitat El Messaoudi S, Rolet F, Mouliere F, Thierry AR (2013) Circulating cell free DNA: preanalytical considerations. Clin Chim Acta 424:222–230PubMed El Messaoudi S, Rolet F, Mouliere F, Thierry AR (2013) Circulating cell free DNA: preanalytical considerations. Clin Chim Acta 424:222–230PubMed
43.
Zurück zum Zitat Jung M, Klotzek S, Lewandowski M, Fleischhacker M, Jung K (2003) Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin Chem 49:1028–1029PubMed Jung M, Klotzek S, Lewandowski M, Fleischhacker M, Jung K (2003) Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin Chem 49:1028–1029PubMed
44.
Zurück zum Zitat Dasari A, Grothey A, Kopetz S (2018) Circulating tumor DNA–defined minimal residual disease in solid tumors: opportunities to accelerate the development of adjuvant therapies. J Clin Oncol 36:3437–3440PubMedCentral Dasari A, Grothey A, Kopetz S (2018) Circulating tumor DNA–defined minimal residual disease in solid tumors: opportunities to accelerate the development of adjuvant therapies. J Clin Oncol 36:3437–3440PubMedCentral
45.
Zurück zum Zitat Cohen JD, Li L, Wang Y et al (2018) Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359:926–930PubMedPubMedCentral Cohen JD, Li L, Wang Y et al (2018) Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359:926–930PubMedPubMedCentral
46.
Zurück zum Zitat Reinert T, Schøler LV, Thomsen R et al (2016) Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut 65:625–634PubMed Reinert T, Schøler LV, Thomsen R et al (2016) Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut 65:625–634PubMed
47.
Zurück zum Zitat Schøler LV, Reinert T, Ørntoft M-BW et al (2017) Clinical implications of monitoring circulating tumor DNA in patients with colorectal cancer. Clin Cancer Res 23:5437–5445PubMed Schøler LV, Reinert T, Ørntoft M-BW et al (2017) Clinical implications of monitoring circulating tumor DNA in patients with colorectal cancer. Clin Cancer Res 23:5437–5445PubMed
48.
Zurück zum Zitat Lindforss U, Zetterquist H, Papadogiannakis N, Olivecrona H (2005) Persistence of K-ras mutations in plasma after colorectal tumor resection. Anticancer Res 25:657–661PubMed Lindforss U, Zetterquist H, Papadogiannakis N, Olivecrona H (2005) Persistence of K-ras mutations in plasma after colorectal tumor resection. Anticancer Res 25:657–661PubMed
49.
Zurück zum Zitat Diehl F, Schmidt K, Choti MA et al (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14:985–990PubMed Diehl F, Schmidt K, Choti MA et al (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14:985–990PubMed
50.
Zurück zum Zitat Tie J, Wang Y, Tomasetti C et al (2016) Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 8:34692–34692 Tie J, Wang Y, Tomasetti C et al (2016) Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 8:34692–34692
51.
Zurück zum Zitat Lu C-Y, Uen Y-H, Tsai H-L et al (2011) Molecular detection of persistent postoperative circulating tumour cells in stages II and III colon cancer patients via multiple blood sampling: prognostic significance of detection for early relapse. Br J Cancer 104:1178–1184PubMedPubMedCentral Lu C-Y, Uen Y-H, Tsai H-L et al (2011) Molecular detection of persistent postoperative circulating tumour cells in stages II and III colon cancer patients via multiple blood sampling: prognostic significance of detection for early relapse. Br J Cancer 104:1178–1184PubMedPubMedCentral
52.
Zurück zum Zitat Sparano J, O’Neill A, Alpaugh K et al (2018) Association of circulating tumor cells with late recurrence of estrogen receptor–positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol 4:1700PubMedPubMedCentral Sparano J, O’Neill A, Alpaugh K et al (2018) Association of circulating tumor cells with late recurrence of estrogen receptor–positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol 4:1700PubMedPubMedCentral
54.
Zurück zum Zitat Siravegna G, Mussolin B, Buscarino M et al (2015) Erratum: clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 21:827PubMed Siravegna G, Mussolin B, Buscarino M et al (2015) Erratum: clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 21:827PubMed
55.
Zurück zum Zitat Van Emburgh BO, Arena S, Siravegna G et al (2016) Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nat Commun 7:13665PubMedPubMedCentral Van Emburgh BO, Arena S, Siravegna G et al (2016) Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nat Commun 7:13665PubMedPubMedCentral
56.
Zurück zum Zitat Wyatt AW, Annala M, Aggarwal R et al (2017) Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer. J Natl Cancer Inst 109:1–9 Wyatt AW, Annala M, Aggarwal R et al (2017) Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer. J Natl Cancer Inst 109:1–9
57.
Zurück zum Zitat Reinhardt F, Franken A, Fehm T, Neubauer H (2017) Navigation through inter- and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer: a potential role for liquid biopsies? Tumor Biol 39:1–15 Reinhardt F, Franken A, Fehm T, Neubauer H (2017) Navigation through inter- and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer: a potential role for liquid biopsies? Tumor Biol 39:1–15
58.
Zurück zum Zitat Chae YK, Davis AA, Jain S et al (2017) Concordance of genomic alterations by next-generation sequencing in tumor tissue versus circulating tumor DNA in breast cancer. Mol Cancer Ther 16:1412–1420PubMed Chae YK, Davis AA, Jain S et al (2017) Concordance of genomic alterations by next-generation sequencing in tumor tissue versus circulating tumor DNA in breast cancer. Mol Cancer Ther 16:1412–1420PubMed
59.
Zurück zum Zitat Pal SK, Sonpavde G, Agarwal N et al (2017) Evolution of circulating tumor DNA profile from first-line to subsequent therapy in metastatic renal cell carcinoma. Eur Urol 72:557–564PubMed Pal SK, Sonpavde G, Agarwal N et al (2017) Evolution of circulating tumor DNA profile from first-line to subsequent therapy in metastatic renal cell carcinoma. Eur Urol 72:557–564PubMed
60.
Zurück zum Zitat Planchard D, Popat S, Kerr K et al (2018) Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Supplement 4):iv192–iv237PubMed Planchard D, Popat S, Kerr K et al (2018) Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Supplement 4):iv192–iv237PubMed
61.
Zurück zum Zitat Kwapisz D (2017) The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer? Ann Transl Med 5:46PubMedPubMedCentral Kwapisz D (2017) The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer? Ann Transl Med 5:46PubMedPubMedCentral
62.
Zurück zum Zitat Rolfo C, Mack PC, Scagliotti GV et al (2018) Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC. J Thorac Oncol 13:1248–1268PubMed Rolfo C, Mack PC, Scagliotti GV et al (2018) Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC. J Thorac Oncol 13:1248–1268PubMed
63.
Zurück zum Zitat Chabon JJ, Simmons AD, Lovejoy AF et al (2016) Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun 7:11815PubMedPubMedCentral Chabon JJ, Simmons AD, Lovejoy AF et al (2016) Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun 7:11815PubMedPubMedCentral
64.
Zurück zum Zitat Mok T, Wu Y-L, Lee JS et al (2015) Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res 21:3196–3203PubMed Mok T, Wu Y-L, Lee JS et al (2015) Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res 21:3196–3203PubMed
65.
66.
Zurück zum Zitat Cohen SJ, Punt CJA, Iannotti N et al (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26:3213–3221 Cohen SJ, Punt CJA, Iannotti N et al (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26:3213–3221
67.
Zurück zum Zitat Germano G, Mauri G, Siravegna G et al (2018) Parallel evaluation of circulating tumor DNA and circulating tumor cells in metastatic colorectal cancer. Clin Colorectal Cancer 17:80–83 Germano G, Mauri G, Siravegna G et al (2018) Parallel evaluation of circulating tumor DNA and circulating tumor cells in metastatic colorectal cancer. Clin Colorectal Cancer 17:80–83
68.
Zurück zum Zitat Khan KH, Cunningham D, Werner B et al (2018) Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial. Cancer Discov 8:1270–1285PubMedPubMedCentral Khan KH, Cunningham D, Werner B et al (2018) Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial. Cancer Discov 8:1270–1285PubMedPubMedCentral
69.
Zurück zum Zitat Vandeputte C, Kehagias P, Housni HE et al (2018) Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor. Oncotarget 9:17756–17769PubMedPubMedCentral Vandeputte C, Kehagias P, Housni HE et al (2018) Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor. Oncotarget 9:17756–17769PubMedPubMedCentral
70.
Zurück zum Zitat Wong ALA, Lim JSJ, Sinha A et al (2015) Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. J Transl Med 13:57PubMedPubMedCentral Wong ALA, Lim JSJ, Sinha A et al (2015) Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. J Transl Med 13:57PubMedPubMedCentral
71.
Zurück zum Zitat Overman MJ, Lonardi S, Wong KYM et al (2018) Durable clinical benefit with nivolumab plus Ipilimumab in DNA mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer. J Clin Oncol 36:773–779PubMed Overman MJ, Lonardi S, Wong KYM et al (2018) Durable clinical benefit with nivolumab plus Ipilimumab in DNA mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer. J Clin Oncol 36:773–779PubMed
72.
Zurück zum Zitat Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520PubMedPubMedCentral Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520PubMedPubMedCentral
73.
Zurück zum Zitat Siravegna G, Corcoran RB (2018) Blood-based prediction of tumor relapse: the cfDNA forecast. Cancer Discov 8:1213–1215PubMed Siravegna G, Corcoran RB (2018) Blood-based prediction of tumor relapse: the cfDNA forecast. Cancer Discov 8:1213–1215PubMed
74.
Zurück zum Zitat Bettegowda C, Sausen M, Leary RJ et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6:22424–22242 Bettegowda C, Sausen M, Leary RJ et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6:22424–22242
75.
Zurück zum Zitat Monticone S, Viola A, Rossato D et al (2015) Adrenal vein sampling in primary aldosteronism: towards a standardised protocol. Lancet Diabetes Endocrinol 3:296–303PubMed Monticone S, Viola A, Rossato D et al (2015) Adrenal vein sampling in primary aldosteronism: towards a standardised protocol. Lancet Diabetes Endocrinol 3:296–303PubMed
76.
Zurück zum Zitat Bidard FC, Huguet F, Louvet C et al (2013) Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. Ann Oncol 24:2057–2061PubMed Bidard FC, Huguet F, Louvet C et al (2013) Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. Ann Oncol 24:2057–2061PubMed
77.
Zurück zum Zitat Jiao LR, Apostolopoulos C, Jacob J et al (2009) Unique localization of circulating tumor cells in patients with hepatic metastases. J Clin Oncol 27:6160–6165PubMed Jiao LR, Apostolopoulos C, Jacob J et al (2009) Unique localization of circulating tumor cells in patients with hepatic metastases. J Clin Oncol 27:6160–6165PubMed
78.
Zurück zum Zitat Reddy RM, Murlidhar V, Zhao L et al (2016) Pulmonary venous blood sampling significantly increases the yield of circulating tumor cells in early-stage lung cancer. J Thorac Cardiovasc Surg 151:852–858PubMed Reddy RM, Murlidhar V, Zhao L et al (2016) Pulmonary venous blood sampling significantly increases the yield of circulating tumor cells in early-stage lung cancer. J Thorac Cardiovasc Surg 151:852–858PubMed
79.
Zurück zum Zitat Siravegna G, Geuna E, Mussolin B et al (2017) Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases. ESMO Open 2:1–6 Siravegna G, Geuna E, Mussolin B et al (2017) Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases. ESMO Open 2:1–6
80.
Zurück zum Zitat Fujii T, Barzi A, Sartore-Bianchi A et al (2017) Mutation-enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced cancers. Clin Cancer Res 23:3657–3666PubMedPubMedCentral Fujii T, Barzi A, Sartore-Bianchi A et al (2017) Mutation-enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced cancers. Clin Cancer Res 23:3657–3666PubMedPubMedCentral
81.
Zurück zum Zitat Kinugasa H, Nouso K, Ako S et al (2018) Liquid biopsy of bile for the molecular diagnosis of gallbladder cancer. Cancer Biol Ther 19:934–938PubMedPubMedCentral Kinugasa H, Nouso K, Ako S et al (2018) Liquid biopsy of bile for the molecular diagnosis of gallbladder cancer. Cancer Biol Ther 19:934–938PubMedPubMedCentral
82.
Zurück zum Zitat Husain H, Nykin D, Bui N et al (2017) Cell-free DNA from ascites and pleural effusions: molecular insights into genomic aberrations and disease biology. Mol Cancer Ther 16:948–955PubMed Husain H, Nykin D, Bui N et al (2017) Cell-free DNA from ascites and pleural effusions: molecular insights into genomic aberrations and disease biology. Mol Cancer Ther 16:948–955PubMed
83.
Zurück zum Zitat Fang Z-T, Wang J-H, Zhang W et al (2014) Circulating tumor cells in the central and peripheral venous compartment – assessing hematogenous dissemination after transarterial chemoembolization of hepatocellular carcinoma. Onco Targets Ther 7:1311–1318PubMedPubMedCentral Fang Z-T, Wang J-H, Zhang W et al (2014) Circulating tumor cells in the central and peripheral venous compartment – assessing hematogenous dissemination after transarterial chemoembolization of hepatocellular carcinoma. Onco Targets Ther 7:1311–1318PubMedPubMedCentral
84.
Zurück zum Zitat Li Y, Huang N, Wang C et al (2018) Impact of liver tumor percutaneous radiofrequency ablation on circulating tumor cells. Oncol Lett 16:2839–2850PubMedPubMedCentral Li Y, Huang N, Wang C et al (2018) Impact of liver tumor percutaneous radiofrequency ablation on circulating tumor cells. Oncol Lett 16:2839–2850PubMedPubMedCentral
85.
Zurück zum Zitat Hong DS, Morris VK, El Osta B et al (2016) Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation. Cancer Discov 6:1352–1365PubMedPubMedCentral Hong DS, Morris VK, El Osta B et al (2016) Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation. Cancer Discov 6:1352–1365PubMedPubMedCentral
86.
Zurück zum Zitat Neri E, Del Re M, Paiar F et al (2018) Radiomics and liquid biopsy in oncology: the holons of systems medicine. Insights Imaging 9:915–924PubMedPubMedCentral Neri E, Del Re M, Paiar F et al (2018) Radiomics and liquid biopsy in oncology: the holons of systems medicine. Insights Imaging 9:915–924PubMedPubMedCentral
87.
Zurück zum Zitat Bardelli A, Pantel K (2017) Liquid biopsies, what we do not know (yet). Cancer Cell 31:172–179PubMed Bardelli A, Pantel K (2017) Liquid biopsies, what we do not know (yet). Cancer Cell 31:172–179PubMed
88.
Zurück zum Zitat Odisio BC, Yamashita S, Huang SY et al (2017) Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status: local tumour progression after ablation of colorectal liver metastases. Br J Surg 104:760–768PubMedPubMedCentral Odisio BC, Yamashita S, Huang SY et al (2017) Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status: local tumour progression after ablation of colorectal liver metastases. Br J Surg 104:760–768PubMedPubMedCentral
89.
Zurück zum Zitat Ziv E, Erinjeri JP, Yarmohammadi H et al (2017) Lung adenocarcinoma: predictive value of KRAS mutation status in assessing local recurrence in patients undergoing image-guided ablation. Radiology 282:251–258PubMed Ziv E, Erinjeri JP, Yarmohammadi H et al (2017) Lung adenocarcinoma: predictive value of KRAS mutation status in assessing local recurrence in patients undergoing image-guided ablation. Radiology 282:251–258PubMed
90.
Zurück zum Zitat Calandri M, Yamashita S, Gazzera C et al (2018) Ablation of colorectal liver metastasis: interaction of ablation margins and RAS mutation profiling on local tumour progression-free survival. Eur Radiol 28:2727–2734PubMed Calandri M, Yamashita S, Gazzera C et al (2018) Ablation of colorectal liver metastasis: interaction of ablation margins and RAS mutation profiling on local tumour progression-free survival. Eur Radiol 28:2727–2734PubMed
91.
Zurück zum Zitat Shady W, Petre EN, Vakiani E et al (2017) Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases. Oncotarget 8:66117–66127PubMedPubMedCentral Shady W, Petre EN, Vakiani E et al (2017) Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases. Oncotarget 8:66117–66127PubMedPubMedCentral
92.
Zurück zum Zitat Ahmed M, Kumar G, Moussa M et al (2016) Hepatic radiofrequency ablation–induced stimulation of distant tumor growth is suppressed by c-met inhibition. Radiology 27:103–117 Ahmed M, Kumar G, Moussa M et al (2016) Hepatic radiofrequency ablation–induced stimulation of distant tumor growth is suppressed by c-met inhibition. Radiology 27:103–117
93.
Zurück zum Zitat Tanis E, Nordlinger B, Mauer M et al (2014) Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. Eur J Cancer 50:912–919 Tanis E, Nordlinger B, Mauer M et al (2014) Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. Eur J Cancer 50:912–919
94.
Zurück zum Zitat Rozenblum N, Zeira E, Scaiewicz V et al (2015) Oncogenesis: an “off-target” effect of radiofrequency ablation. Radiology 276:426–432PubMed Rozenblum N, Zeira E, Scaiewicz V et al (2015) Oncogenesis: an “off-target” effect of radiofrequency ablation. Radiology 276:426–432PubMed
95.
Zurück zum Zitat Veltri A, Calandri M (2019) Thermal ablation and systemic therapies in the metastatic liver: time for a “glocal” approach. Eur Radiol 29:5042–5044PubMed Veltri A, Calandri M (2019) Thermal ablation and systemic therapies in the metastatic liver: time for a “glocal” approach. Eur Radiol 29:5042–5044PubMed
96.
Zurück zum Zitat Kim C, Hoang CD, Kesarwala AH, Schrump DS, Guha U, Rajan A (2017) Role of local ablative therapy in patients with oligometastatic and oligoprogressive non-small cell lung cancer. J Thorac Oncol 12:179–193PubMed Kim C, Hoang CD, Kesarwala AH, Schrump DS, Guha U, Rajan A (2017) Role of local ablative therapy in patients with oligometastatic and oligoprogressive non-small cell lung cancer. J Thorac Oncol 12:179–193PubMed
97.
Zurück zum Zitat Ni Y, Liu B, Ye X et al (2019) Local thermal ablation with continuous EGFR tyrosine kinase inhibitors for EGFR-mutant non-small cell lung cancers that developed extra-central nervous system (CNS) oligoprogressive disease. Cardiovasc Intervent Radiol 42:693–699PubMed Ni Y, Liu B, Ye X et al (2019) Local thermal ablation with continuous EGFR tyrosine kinase inhibitors for EGFR-mutant non-small cell lung cancers that developed extra-central nervous system (CNS) oligoprogressive disease. Cardiovasc Intervent Radiol 42:693–699PubMed
Metadaten
Titel
Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know
verfasst von
Marco Calandri
Giulia Siravegna
Steven M. Yevich
Giuseppe Stranieri
Carlo Gazzera
Scott Kopetz
Paolo Fonio
Sanjay Gupta
Alberto Bardelli
Andrea Veltri
Bruno C. Odisio
Publikationsdatum
19.03.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 8/2020
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-020-06700-4

Weitere Artikel der Ausgabe 8/2020

European Radiology 8/2020 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.